* Novo set to pay Hengrui up to $2.6 billion for rights to pill * China develops nearly 250 experimental treatments * Hengrui candidate shows potential for once-weekly dosage (Adds investor comment in
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Vallari Srivastava, Curtis Williams and David French HOUSTON, Sept 29 (Reuters) - Alternative asset…
By Foo Yun Chee BRUSSELS, Sept 29 (Reuters) - Alphabet's Google has challenged two EU…
By Ryan Patrick Jones TORONTO, Sept 29 (Reuters) - Three generations of an Armenian-Christian family…
Sept 29 (Reuters) - Cettire Ltd: * CETTIRE - EXECUTES NON-BINDING TERM SHEET TO FACTOR…
VIDEO SHOWS: SOUNDBITES FROM FORMER WORLD NUMBER FOUR AND JAPAN'S KEI NISHIKORI AHEAD OF HIS…
By Echo Wang Sept 28 (Reuters) - Anthropic is making a massive bet that AI…